Skip to content
10-K

Annual Report

SAB Biotherapeutics, Inc. SABS SABSW

0001833214-26-000003

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 50.95M sh
Shares Diluted FY 2025 · Dec 31, 2025 61.34M sh
Shares Diluted FY 2025 · Dec 31, 2024 9.26M sh
Capex FY 2025 · Dec 31, 2025 $933.16K
Capex FY 2025 · Dec 31, 2024 $337.26K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$44.78M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$34.29M
Short Term Investments FY 2025 · Dec 31, 2025 $86.09M
Short Term Investments FY 2025 · Dec 31, 2024 $11.86M
Cash And Equivalents FY 2025 · Dec 31, 2025 $10.5M
Cash And Equivalents FY 2025 · Dec 31, 2024 $8.9M
Stockholders Equity FY 2025 · Dec 31, 2025 $151.49M
Stockholders Equity FY 2025 · Dec 31, 2024 $25.97M
Stockholders Equity FY 2025 · Dec 31, 2023 $57.3M
Current Liabilities FY 2025 · Dec 31, 2025 $10.68M
Current Liabilities FY 2025 · Dec 31, 2024 $7.98M
Total Liabilities FY 2025 · Dec 31, 2025 $21.32M
Total Liabilities FY 2025 · Dec 31, 2024 $18.23M
Current Assets FY 2025 · Dec 31, 2025 $101.05M
Current Assets FY 2025 · Dec 31, 2024 $23.79M
Total Assets FY 2025 · Dec 31, 2025 $172.81M
Total Assets FY 2025 · Dec 31, 2024 $44.2M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.79
Eps Diluted FY 2025 · Dec 31, 2024 −$3.68
Eps Basic FY 2025 · Dec 31, 2025 $0.22
Eps Basic FY 2025 · Dec 31, 2024 −$3.68
Sga Expense FY 2025 · Dec 31, 2025 $14.6M
Sga Expense FY 2025 · Dec 31, 2024 $13.98M
Rd Expense FY 2025 · Dec 31, 2025 $34.35M
Rd Expense FY 2025 · Dec 31, 2024 $30.25M
Net Income FY 2025 · Dec 31, 2025 $13.27M
Net Income FY 2025 · Dec 31, 2024 −$34.11M
Operating Income FY 2025 · Dec 31, 2025 −$48.95M
Operating Income FY 2025 · Dec 31, 2024 −$42.91M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $1.32M